Ensign Peak Advisors
IMNM icon

Ensign Peak Advisors’s Immunome IMNM Stock Holding History

Ensign Peak Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Hold
7,700
– – ﹤0.01% 1395
2025
Q4 		$165K Buy
+7,700
New +$135K ﹤0.01% 1399
2024
Q3 		– Sell
-113,934
Closed -$1.38M – 1712
2024
Q2 		$1.38M Buy
+113,934
New +$1.78M ﹤0.01% 1081

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Ensign Peak Advisors's IMNM Position: Q1 2026 in Review

Ensign Peak Advisors held its Immunome (IMNM) position steady in Q1 2026 at 7,700 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

Ensign Peak Advisors first reported a position in IMNM in Q2 2024 and has held it in 3 quarters since. The position peaked at $1.38M in Q2 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Ensign Peak Advisors held 7,700 shares of Immunome worth $168K as of Q1 2026.
  • Ensign Peak Advisors left its Immunome share count unchanged in Q1 2026.
  • Immunome made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1395 holding.
  • Ensign Peak Advisors first reported a position in Immunome in Q2 2024 and has held it in 3 quarters since.
  • Ensign Peak Advisors's Immunome position peaked at $1.38M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.